With advances in traumatic wound care, the question is no longer whether we can close the wound, but how well we can restore what was lost.
Key takeaways:
- Wound closure has long been the default measure of success in acute wound care; However, for patients, it is rarely the milestone that matters.
- Regenerative technologies, including autologous cell systems and dermal scaffolds, now allow for higher quality and more functional results.
- Published evidence links these approaches to shorter hospital stays and significant per-patient cost reductions
- Health systems that follow patients after discharge are discovering substantial human and financial value that episode-based metrics miss.
Closing is a milestone, not a result.
There is a moment in the treatment of a traumatic wound when surgeons feel that their goal is accomplished: the wound is closed, the graft intact, and the dressing clean. For decades, closure has been considered the primary measure of success, determining how we train surgeons, design care pathways, evaluate technologies, and report outcomes. Almost all of the metrics we track, the benchmarks we set, and the reimbursement structures we’ve created are anchored in this point.
Meanwhile, patients return home with grafted skin that tightens on their shoulders when they reach for a shelf. Avoid sleeveless shorts. They reject handshakes. They abandon jobs that require physical labor. They carry the wound long after the history indicates it is closed.
We can and must do better for our patients, and technology is now available to demand more.
The skin does more than cover the body
The skin is not decorative. It regulates body temperature, protects against infection, enables sensation, and provides the flexible architecture that allows movement. When trauma or burns occur, replacing injured skin should be considered the minimum, not the goal.
Split-thickness skin grafting, the dominant technique for decades, provides good coverage but is less effective for restoration. Grafts often differ in color and texture from native skin. They can harden and contract, especially over the joints, creating a permanent mechanical disadvantage in the part of the body that the patient needs most. The donor harvest site opens a second wound that can be extremely painful, cause secondary infection, and leave a visible scar.
We have accepted these compensations because, for a long time, the coverage was sufficient. It is no longer. Now it should be the bare minimum.
Align measurement with technological advances
Regenerative medicine has quietly transformed what is possible in reconstructive surgery. Point-of-care autologous cell systems can now take a postage stamp-sized skin sample, process the patient’s own cells, and deliver them directly to a wound, supporting the regeneration of tissue that more closely resembles native skin in pigmentation, flexibility, and quality. Is been found that in patients with deep partial thickness burns, treatment with aerosol skin cell technology alone significantly reduced donor skin requirements by 97.5% compared to autograft with 2:1 mesh. Smaller donor sites mean less pain and a faster recovery. Better tissue quality means less contracture and better long-term mobility. Faster closure means less risk of infection. Combined, the patient leaves the hospital earlier to recover at home.
Dermal scaffolding technologies are rebuilding the foundation beneath grafts, accelerating vascularization and creating the biological conditions for durable, resilient tissue. These are not experimental curiosities, but rather available tools that surgeons are already using.
However, adoption remains uneven, largely because incentive structures do not reward outcomes that improve these technologies. If a health system’s wound care program is evaluated based on closure rates and length of stay, there is no data signal for “patient regained full shoulder motion” or “revision surgery not required at 18 months.” The benefit is real. It’s just not measured.
The cost argument is stronger than you think
Advanced therapies cost more upfront. Unfortunately, this is also where analysis often stops, and where it shouldn’t.
A patient who avoids scar contracture does not require revision surgery. A patient with better healing of the donor site is discharged sooner and requires less pain treatment. A trauma survivor who regains full function returns to work rather than entering a disability pathway. Studies have found that skin spray technology can reduce length of hospital stay by an average of 3.3 days, resulting in cost savings of nearly $37,000 per patient with burns up to 50% TBSA. Economic modeling suggests Length of hospital stay alone accounts for up to 70% of those cost reductions. When you follow the downstream economics instead of dwelling on the cost of the initial procedure, the math adds up.
Health systems that have built the data infrastructure to track functional outcomes, readmissions, and long-term resource utilization are beginning to see this. Those who still measure the success of wound care at the time of closure are measuring the episode, not the recovery. The difference, both in human and financial terms, is significant.
What we owe to patients and ourselves
For a trauma survivor, feeling comfortable in your skin is not a luxury outcome. That’s the point. The ability to move without restrictions, to feel comfortable with your appearance, to return to work and relationships, and simply to everyday life, is what recovery really means to the person experiencing it.
Healthcare leaders have both the opportunity and obligation to create systems that follow that standard. That means updating outcomes frameworks to capture function, aesthetics and quality of life. It means evaluating wound care technologies in relation to the entire patient recovery process, not just the acute episode. And it means being willing to challenge the comfortable assumption that closure is enough.
The tools to do it better exist and the evidence is there. The only thing still missing is the will to redefine what success looks like and hold our systems accountable for achieving it.
Closing a wound is where the surgery ends. Restoring a life is where caring begins.
About Saeed A. Chowdhry, MD
Saeed A. Chowdhry, MD, He has a very active clinical practice in the Chicago area and also serves as an Associate Professor of Plastic Surgery at the Rosalind Franklin University of Medicine and Sciences, also known as the Chicago Medical School. Dr. Chowdhry is the President and Chief of Plastic Surgery at Christ Hospital in the Chicago area. With nearly 800 beds, it is one of the busiest tertiary care referral and Level I trauma centers in the Midwest.
He was educated at Rush University School of Medicine and subsequently completed his training in General Surgery at the University of Illinois at Mt. Sinai and his fellowship training in Plastic Surgery at the University of Louisville. During his training and practice, he has won several research and teaching awards. He is the author of peer-reviewed journal articles and book chapters that have been reviewed and cited more than a thousand times in the surgical literature. Dr. Chowdhry has also served as a reviewer for several journals, as well as the Cochrane Review, and has been recognized for his expertise in cosmetic and reconstructive surgery.
